C
Codexis, Inc. (CDXS)
NMS – Real Time Price. Currency in USD
1.61
+0.13 (8.83%)
Market open: Aug 12, 2026, 11:07 AM EDT
1.53
+0.05 (3.39%)
Previous after-hours: Aug 11, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.61
+0.13 (8.83%)
Market open: Aug 12, 2026, 11:07 AM EDT
1.53
+0.05 (3.39%)
Previous after-hours: Aug 11, 2026, 7:58 PM EDT
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Name | Position |
|---|---|
| Dr. Alison Moore Ph.D. | President, CEO & Director |
| Dr. Stefan Lutz Ph.D. | Chief Scientific Officer |
| Mr. Britton Jimenez | Senior Vice President of Sales & Marketing |
| Mr. John Schiffhauer | Senior Vice President of Intellectual Property |
| Ms. Georgia L. Erbez | CFO & Chief Business Officer |
| Ms. Karen Frechou-Armijo | Senior VP & Head of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-08-11 | 10-Q | cdxs-20260630.htm |
| 2026-07-27 | 8-K | d158208d8k.htm |
| 2026-07-23 | 8-K | d24920d8k.htm |
| 2026-06-22 | 8-K | d152173d8k.htm |
| 2026-05-07 | 8-K | d112205d8k.htm |
| 2026-04-28 | DEFA14A | d16434ddefa14a.htm |
| 2026-04-28 | DEF 14A | d939868ddef14a.htm |
| 2026-04-28 | ARS | d104206dars.pdf |
| 2026-04-14 | 8-K | d96482d8k.htm |
| 2026-03-11 | 8-K | d106216d8k.htm |